Bupropion inhibits cytochrome P450 2D6,5 which is the enzyme that converts venlafaxine into an active metabolite, desvenlafaxine. When CYP2D6 is inhibited, venlafaxine levels rise at the expense of desvenlafaxine. Because the renal excretion of venlafaxine is small, the consequence is increased dose-dependent venlafaxine-related adverse effects.

Teva Pharmaceuticals is the primary supplier of both branded and generic versions of the stimulant, which is approved to treat ADHD and narcolepsy. Teva has cited increased demand, workforce shortages, and manufacturing disruptions due to packaging constraints as reasons for the supply problems.

In 2023, patents for the two blockbusters Humira and Stelara will expire. The patents for Aranesp, Rituxan, Simponi, and others will expire in 2024, and in 2025, six more blockbuster drugs will experience patent expiration, opening the field to a rush of biosimilars. That could create an environment of significantly reduced drug prices.

Seven-hundred patients with left ventricular ejection fraction (LVEF) of 35% or less, extensive coronary artery disease amenable to PCI, and demonstrable myocardial viability were randomly assigned to PCI plus optimal medical therapy vs. optimal medical therapy alone. At 6 months, the LVEF was similar between the two groups.

The IV-equivalent formulation is indicated for the treatment of congestion due to fluid overload in people with NYHA class II/III chronic heart failure and may offer a substantial change in the management of the condition.

When compared with rivaroxaban in a propensity score–matched cohort of 19,894 patients, apixaban was associated with an approximately 50% lower rate of ischemic stroke or systemic embolism and bleeding compared to rivaroxaban.